ACURX PHARMACEUTICALS INC (ACXP)

US00510M1045 - Common Stock

2.36  +0.03 (+1.29%)

Fundamental Rating

2

Taking everything into account, ACXP scores 2 out of 10 in our fundamental rating. ACXP was compared to 592 industry peers in the Biotechnology industry. The financial health of ACXP is average, but there are quite some concerns on its profitability. ACXP has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year ACXP has reported negative net income.
In the past year ACXP has reported a negative cash flow from operations.
ACXP had negative earnings in each of the past 5 years.
In the past 5 years ACXP always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -189.06%, ACXP is doing worse than 90.14% of the companies in the same industry.
ACXP has a worse Return On Equity (-312.31%) than 76.70% of its industry peers.
Industry RankSector Rank
ROA -189.06%
ROE -312.31%
ROIC N/A
ROA(3y)-138.07%
ROA(5y)-158.29%
ROE(3y)-193.43%
ROE(5y)-294.76%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ACXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACXP has more shares outstanding
ACXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ACXP has an Altman-Z score of -8.85. This is a bad value and indicates that ACXP is not financially healthy and even has some risk of bankruptcy.
ACXP has a Altman-Z score of -8.85. This is in the lower half of the industry: ACXP underperforms 76.87% of its industry peers.
ACXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.85
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ACXP has a Current Ratio of 2.53. This indicates that ACXP is financially healthy and has no problem in meeting its short term obligations.
ACXP has a worse Current ratio (2.53) than 73.81% of its industry peers.
ACXP has a Quick Ratio of 2.53. This indicates that ACXP is financially healthy and has no problem in meeting its short term obligations.
ACXP's Quick ratio of 2.53 is on the low side compared to the rest of the industry. ACXP is outperformed by 71.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 2.53

1

3. Growth

3.1 Past

The earnings per share for ACXP have decreased by -1.79% in the last year.
EPS 1Y (TTM)-1.79%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-32.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 15.28% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.74%
EPS Next 2Y-15.07%
EPS Next 3Y9.45%
EPS Next 5Y15.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

ACXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.07%
EPS Next 3Y9.45%

0

5. Dividend

5.1 Amount

ACXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (3/28/2024, 12:02:39 PM)

2.36

+0.03 (+1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.50M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -189.06%
ROE -312.31%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.53
Quick Ratio 2.53
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1.79%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y